BOSTON, Nov. 24, 2021 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that management will participate in a fireside chat at Piper Sandler’s 33rd Annual Virtual Healthcare Conference on Thursday, December 2, 2021 at 10:30 a.m. ET.
The fireside chat will be available via live webcast through the Events & Presentations page of the Investors + Media section of the company’s website at www.praxismedicines.com. A replay of the webcast will be available on Praxis’ website for 90 days following the event.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying insights from genetic epilepsies to broader neurological and psychiatric disorders, using our understanding of shared biological targets and circuits in the brain. Praxis has established a broad portfolio, including multiple disclosed programs across CNS disorders including depression, epilepsy, movement disorders and pain syndromes, with three clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on LinkedIn and Twitter.
CONTACT: Investor Contact: Alex Kane Praxis Precision Medicines investors@praxismedicines.com 617-300-8481 Media Contact: Ian Stone Canale Communications Ian.stone@canalecomm.com 619-849-5388
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, today…
Toronto, Ontario--(Newsfile Corp. - June 14, 2024) - Justera Health Ltd. (CSE: VTAL) (OTC Pink:…
Partner’s software products and services are utilized by hundreds of life science organizations, including the…
MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits disease progression, pro-inflammatory cytokines and autoantibody production…
Acquisition expected to be synergistic with FOXO’s epigenetic technology in community health and addiction recovery…
MARKHAM, Ontario, June 14, 2024 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the…